Mitochondrial bioenergetics in the metabolic myopathy accompanying peripheral artery disease

Victoria G. Rontoyanni, Omar Nunez Lopez, Grant Fankhauser, Zulfiqar Cheema, Blake Rasmussen, Craig Porter

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Peripheral artery disease (PAD) is a serious but relatively underdiagnosed and undertreated clinical condition associated with a marked reduction in functional capacity and a heightened risk of morbidity and mortality. The pathophysiology of lower extremity PAD is complex, and extends beyond the atherosclerotic arterial occlusion and subsequent mismatch between oxygen demand and delivery to skeletal muscle mitochondria. In this review, we evaluate and summarize the available evidence implicating mitochondria in the metabolic myopathy that accompanies PAD. Following a short discussion of the available in vivo and in vitro methodologies to quantitate indices of muscle mitochondrial function, we review the current evidence implicating skeletal muscle mitochondrial dysfunction in the pathophysiology of PAD myopathy, while attempting to highlight questions that remain unanswered. Given the rising prevalence of PAD, the detriment in quality of life for patients, and the associated significant healthcare resource utilization, new alternate therapies that ameliorate lower limb symptoms and the functional impairment associated with PAD are needed. A clear understanding of the role of mitochondria in the pathophysiology of PAD may contribute to the development of novel therapeutic interventions.

Original languageEnglish (US)
Article number141
JournalFrontiers in Physiology
Volume8
Issue numberMAR
DOIs
StatePublished - Mar 13 2017

Fingerprint

Peripheral Arterial Disease
Muscular Diseases
Energy Metabolism
Lower Extremity
Mitochondria
Skeletal Muscle
Muscle Mitochondrion
Quality of Life
Oxygen
Morbidity
Delivery of Health Care
Muscles
Mortality
Therapeutics

Keywords

  • Bioenergetics
  • Mitochondria
  • Mitochondrial function
  • Peripheral artery disease
  • Peripheral vascular disease
  • Skeletal muscle

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Mitochondrial bioenergetics in the metabolic myopathy accompanying peripheral artery disease. / Rontoyanni, Victoria G.; Lopez, Omar Nunez; Fankhauser, Grant; Cheema, Zulfiqar; Rasmussen, Blake; Porter, Craig.

In: Frontiers in Physiology, Vol. 8, No. MAR, 141, 13.03.2017.

Research output: Contribution to journalReview article

Rontoyanni, Victoria G. ; Lopez, Omar Nunez ; Fankhauser, Grant ; Cheema, Zulfiqar ; Rasmussen, Blake ; Porter, Craig. / Mitochondrial bioenergetics in the metabolic myopathy accompanying peripheral artery disease. In: Frontiers in Physiology. 2017 ; Vol. 8, No. MAR.
@article{3c2c0b72d73d43a7953ab536c29d5b67,
title = "Mitochondrial bioenergetics in the metabolic myopathy accompanying peripheral artery disease",
abstract = "Peripheral artery disease (PAD) is a serious but relatively underdiagnosed and undertreated clinical condition associated with a marked reduction in functional capacity and a heightened risk of morbidity and mortality. The pathophysiology of lower extremity PAD is complex, and extends beyond the atherosclerotic arterial occlusion and subsequent mismatch between oxygen demand and delivery to skeletal muscle mitochondria. In this review, we evaluate and summarize the available evidence implicating mitochondria in the metabolic myopathy that accompanies PAD. Following a short discussion of the available in vivo and in vitro methodologies to quantitate indices of muscle mitochondrial function, we review the current evidence implicating skeletal muscle mitochondrial dysfunction in the pathophysiology of PAD myopathy, while attempting to highlight questions that remain unanswered. Given the rising prevalence of PAD, the detriment in quality of life for patients, and the associated significant healthcare resource utilization, new alternate therapies that ameliorate lower limb symptoms and the functional impairment associated with PAD are needed. A clear understanding of the role of mitochondria in the pathophysiology of PAD may contribute to the development of novel therapeutic interventions.",
keywords = "Bioenergetics, Mitochondria, Mitochondrial function, Peripheral artery disease, Peripheral vascular disease, Skeletal muscle",
author = "Rontoyanni, {Victoria G.} and Lopez, {Omar Nunez} and Grant Fankhauser and Zulfiqar Cheema and Blake Rasmussen and Craig Porter",
year = "2017",
month = "3",
day = "13",
doi = "10.3389/fphys.2017.00141",
language = "English (US)",
volume = "8",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",
number = "MAR",

}

TY - JOUR

T1 - Mitochondrial bioenergetics in the metabolic myopathy accompanying peripheral artery disease

AU - Rontoyanni, Victoria G.

AU - Lopez, Omar Nunez

AU - Fankhauser, Grant

AU - Cheema, Zulfiqar

AU - Rasmussen, Blake

AU - Porter, Craig

PY - 2017/3/13

Y1 - 2017/3/13

N2 - Peripheral artery disease (PAD) is a serious but relatively underdiagnosed and undertreated clinical condition associated with a marked reduction in functional capacity and a heightened risk of morbidity and mortality. The pathophysiology of lower extremity PAD is complex, and extends beyond the atherosclerotic arterial occlusion and subsequent mismatch between oxygen demand and delivery to skeletal muscle mitochondria. In this review, we evaluate and summarize the available evidence implicating mitochondria in the metabolic myopathy that accompanies PAD. Following a short discussion of the available in vivo and in vitro methodologies to quantitate indices of muscle mitochondrial function, we review the current evidence implicating skeletal muscle mitochondrial dysfunction in the pathophysiology of PAD myopathy, while attempting to highlight questions that remain unanswered. Given the rising prevalence of PAD, the detriment in quality of life for patients, and the associated significant healthcare resource utilization, new alternate therapies that ameliorate lower limb symptoms and the functional impairment associated with PAD are needed. A clear understanding of the role of mitochondria in the pathophysiology of PAD may contribute to the development of novel therapeutic interventions.

AB - Peripheral artery disease (PAD) is a serious but relatively underdiagnosed and undertreated clinical condition associated with a marked reduction in functional capacity and a heightened risk of morbidity and mortality. The pathophysiology of lower extremity PAD is complex, and extends beyond the atherosclerotic arterial occlusion and subsequent mismatch between oxygen demand and delivery to skeletal muscle mitochondria. In this review, we evaluate and summarize the available evidence implicating mitochondria in the metabolic myopathy that accompanies PAD. Following a short discussion of the available in vivo and in vitro methodologies to quantitate indices of muscle mitochondrial function, we review the current evidence implicating skeletal muscle mitochondrial dysfunction in the pathophysiology of PAD myopathy, while attempting to highlight questions that remain unanswered. Given the rising prevalence of PAD, the detriment in quality of life for patients, and the associated significant healthcare resource utilization, new alternate therapies that ameliorate lower limb symptoms and the functional impairment associated with PAD are needed. A clear understanding of the role of mitochondria in the pathophysiology of PAD may contribute to the development of novel therapeutic interventions.

KW - Bioenergetics

KW - Mitochondria

KW - Mitochondrial function

KW - Peripheral artery disease

KW - Peripheral vascular disease

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=85016151496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016151496&partnerID=8YFLogxK

U2 - 10.3389/fphys.2017.00141

DO - 10.3389/fphys.2017.00141

M3 - Review article

VL - 8

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

IS - MAR

M1 - 141

ER -